Clinical Edge Journal Scan

Atopic dermatitis positively linked with the risk for incident venous thromboembolism


 

Key clinical point: Adults with atopic dermatitis (AD) have a 1.28-fold increased risk for incident venous thromboembolism (VTE) compared with those without AD.

Major finding: Patients with AD vs control individuals without AD had an increased risk for incident VTE (hazard ratio [HR] 1.28; 95% CI 1.17-1.40), with the risk being elevated for both deep vein thrombosis (HR 1.26; 95% CI 1.14-1.40) and pulmonary embolism (HR 1.30; 95% CI 1.08-1.57).

Study details: The data come from a retrospective cohort study that included 142,429 patients age 20 years with AD and 142,429 matched control individuals without AD.

Disclosures: This study was funded by Hualien Tzu Chi Hospital, Taiwan. The authors declared no conflicts of interest.

Source: Chen TL et al. Risk of venous thromboembolism among adults with atopic dermatitis. JAMA Dermatol. 2023 (May 31). doi: 10.1001/jamadermatol.2023.1300.

Recommended Reading

Single-strain probiotic lactobacilli: An up-and-coming adjuvant therapy for atopic dermatitis
MDedge Dermatology
AD in infancy: Diagnostic advice and treatment tips
MDedge Dermatology
Can online mindfulness and self-compassion training improve quality of life for patients with atopic dermatitis?
MDedge Dermatology
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
MDedge Dermatology
Commentary: AD, RA, Probiotics, and a New JAK inhibitor, June 2023
MDedge Dermatology
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
MDedge Dermatology
Dupilumab outcomes stable at end of open label atopic dermatitis study
MDedge Dermatology
Abrocitinib remains effective at 96 weeks, in older as well as younger adults
MDedge Dermatology
Advising patients on AD treatment options: Expert pearls
MDedge Dermatology
A live topical biotherapeutic spray improves pruritus in atopic dermatitis
MDedge Dermatology